2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
32
Breast Neoplasms
21
Neoplasms
17
Prostatic Neoplasms
11
Obesity
8
Sarcopenia
6
Colorectal Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Polycystic Ovary Syndrome
4
Signs and Symptoms
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Overweight
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia
2
Laryngeal Neoplasms
2
Insulin Resistance
2
Hematopoietic and Lymphatic System Neoplasm
2
Endometrial Neoplasms
2
Interventions
Rituximab
112
Cyclophosphamide
103
fludarabine
61
Doxorubicin
33
Vincristine
31
Etoposide
31
Prednisone
30
Lenalidomide
24
ibrutinib
22
fludarabine phosphate
21
Immunotherapy, Adoptive
19
Bendamustine Hydrochloride
19
obinutuzumab
18
Cytarabine
18
pembrolizumab
16
Magnetic Resonance Spectroscopy
16
Bortezomib
14
Specimen Handling
13
Dexamethasone
13
polatuzumab vedotin
12
CT-P10
12
venetoclax
11
Gemcitabine
11
Carboplatin
11
pirtobrutinib
10
glofitamab
10
zanubrutinib
9
Nivolumab
9
Mycophenolic Acid
9
Melphalan
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Resistance Training
×
Clear all
NCT05556239
2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA
Completed
42 enrolled